Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -48.92% is 12% above its 5-year average of -55.42%, around the middle of its 5-year range (-82.73%–-31.06%).
As of the fiscal period ended Tuesday, June 30, 2026. 30.92% above its 12-month average of -70.81%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -48.92%.
RETURN ON INVESTED CAPITAL (ROIC)
-48.92%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-70.81%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-63.84%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-55.42%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
-42.22%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
+30.92%
CURRENT VS 3Y AVG
+23.38%
CURRENT VS 5Y AVG
+11.73%
CURRENT VS 10Y AVG
-15.86%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-35.07%
median of 785 covered companies
CURRENT VS SECTOR MEDIAN
-39.48%
vs the sector median at left
Rocket Pharmaceuticals, Inc.
Market Cap
$271.35M
Return on Invested Capital (ROIC)
-48.92%
TTM Avg
-70.81%
3Y Avg
-63.84%
5Y Avg
-55.42%
Market Cap
$271.10M
Return on Invested Capital (ROIC)
-58.72%
TTM Avg
-52.25%
3Y Avg
-49.23%
5Y Avg
-41.07%
Market Cap
$270.62M
Return on Invested Capital (ROIC)
-31.62%
TTM Avg
-73.81%
3Y Avg
-69.44%
5Y Avg
-42.80%
Market Cap
$270.52M
Return on Invested Capital (ROIC)
-37.64%
TTM Avg
-32.22%
3Y Avg
-29.09%
5Y Avg
-21.19%
Market Cap
$269.06M
Return on Invested Capital (ROIC)
-59.50%
TTM Avg
-188.11%
3Y Avg
-308.62%
5Y Avg
-250.56%
Market Cap
$267.65M
Return on Invested Capital (ROIC)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$265.40M
Return on Invested Capital (ROIC)
-15.00%
TTM Avg
-11.69%
3Y Avg
-3.29%
5Y Avg
-2.92%
Market Cap
$264.16M
Return on Invested Capital (ROIC)
-43.56%
TTM Avg
-66.27%
3Y Avg
-114.94%
5Y Avg
-104.61%
Market Cap
$262.74M
Return on Invested Capital (ROIC)
-170.19%
TTM Avg
-56.97%
3Y Avg
-50.85%
5Y Avg
-45.83%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Rocket Pharmaceuticals, Inc. (RCKT) | $271.35M | -48.92% | -70.81% | -63.84% | -55.42% |
| Fate Therapeutics, Inc. (FATE)vs › | $271.10M | -58.72% | -52.25% | -49.23% | -41.07% |
| SAB Biotherapeutics, Inc. (SABS)vs › | $270.62M | -31.62% | -73.81% | -69.44% | -42.80% |
| Treace Medical Concepts, Inc. (TMCI)vs › | $270.52M | -37.64% | -32.22% | -29.09% | -21.19% |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $269.06M | -59.50% | -188.11% | -308.62% | -250.56% |
| Scribe Therapeutics Inc. (SCTX)vs › | $267.65M | N/A | N/A | N/A | N/A |
| OraSure Technologies, Inc. (OSUR)vs › | $265.40M | -15.00% | -11.69% | -3.29% | -2.92% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $264.16M | -43.56% | -66.27% | -114.94% | -104.61% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $262.74M | -170.19% | -56.97% | -50.85% | -45.83% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $263.41M | -42.92% | -30.10% | -80.25% | -64.52% |
ROIC
-48.9%
ROE
-4.7%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -48.92% |
| 2026-03-31 | -82.73% |
| 2025-12-31 | -77.19% |
| 2025-09-30 | -74.36% |
| 2025-06-30 | -70.89% |
| 2025-03-31 | -62.01% |
| 2024-12-31 | -56.10% |
| 2024-09-30 | -77.41% |
| 2024-06-30 | -65.99% |
| 2024-03-31 | -56.77% |
| 2023-12-31 | -50.14% |
| 2023-09-30 | -46.96% |
| 2023-06-30 | -60.48% |
| 2023-03-31 | -50.45% |
| 2022-12-31 | -43.76% |
| 2022-09-30 | -51.56% |
| 2022-06-30 | -46.80% |
| 2022-03-31 | -38.99% |
| 2021-12-31 | -35.22% |
| 2021-09-30 | -36.02% |
| 2021-06-30 | -31.06% |
| 2021-03-31 | -27.62% |
| 2020-12-31 | -23.85% |
| 2020-09-30 | -30.72% |
| 2020-06-30 | -26.02% |
| 2020-03-31 | -23.13% |
| 2019-12-31 | -21.52% |
| 2019-09-30 | -29.90% |
| 2019-06-30 | -26.98% |
| 2019-03-31 | -34.16% |
| 2018-12-31 | -30.16% |
| 2018-09-30 | -26.43% |
| 2018-06-30 | -20.36% |
| 2018-03-31 | -14.86% |
| 2017-12-31 | -27.36% |
| 2017-09-30 | -34.47% |
| 2017-06-30 | -36.23% |
| 2017-03-31 | -37.02% |
| 2016-12-31 | -34.21% |
| 2016-09-30 | -28.22% |
| 2016-06-30 | -34.02% |
| 2016-03-31 | -27.60% |
| 2015-12-31 | -18.68% |
| 2015-09-30 | -11.88% |
| 2015-06-30 | -21.38% |
| 2015-03-31 | -17.04% |
| 2014-12-31 | -265.47% |
| 2014-09-30 | -128.15% |
